OJOG  Vol.9 No.2 , February 2019
Techniques for Determining the Treatment Costs of Cervical Cancer: A Systematic Review
Background: Uterine cervical cancer (UCC) represents a public health problem in many part of the world. The use of new technologies is leading to increased treatment costs, resulting in a substantial economic impact worldwide. Standardization of economic evaluation methods is needed to improve comparisons between jurisdictions. Objective: To identify the methods used to measure the cost of treating invasive UCC, and to search for correlations between cancer treatment expenditures and local economies. Methods: We searched articles in MEDLINE, LILACS, and SciELO with no language restrictions, and included publications from January 01, 2007 to December 31, 2016. Studies were included if they described the annual direct cost of invasive cervical cancer and detailed the costing method. Complete economic evaluations were excluded. Results were described in 2016 international dollars. Results: Of 1581 studies initially reviewed, 13 articles were included in the analysis. Six articles used a bottom-up; six used a top-down approach and one used both. Annual cost per patient varied from I$ 2146.22 (Poland) to 34,351.54 (Sweden). Middle-income countries (MIC) spent median 72.52% of its GDP per capita on the treatment of invasive cervical cancer, while high-income countries (HIC) spent median 30.12% (p = 0.032). No significant difference was found when separated by costing method. Conclusions: We found that, for the treatment costs of invasive UCC, the percentages of GDP per capita were statistically higher in MIC than in HIC. However, no significant difference was found between costing methods, and the top-down approach could be used.
Cite this paper
Santos, C. , Souza, A. and Vidal, S. (2019) Techniques for Determining the Treatment Costs of Cervical Cancer: A Systematic Review. Open Journal of Obstetrics and Gynecology, 9, 117-128. doi: 10.4236/ojog.2019.92012.
[1]   World Health Organization IA for R on C (2012) Estimated Incidence, Mortality and Prevalence Worldwide in 2012.

[2]   Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians; 65, 87-108.

[3]   Formen D., Ferlay J., Stewart, B.W. and Wild, C.P. (2014) The Global and Regional Burden of Cancer. In: Stewart, B.W. and Wild, C.P., Eds., World Cancer Report 2014, IARC, International Agency for Research on Cancer, World Health Organization, Lyon.

[4]   Goss, P.E., Lee, B.L., Badovinac-Crnjevic, T., et al. (2013) Planning Cancer Control in Latin America and the Caribbean. Lancet Oncology, 14, 391-436.

[5]   The World Bank (2016) The World Bank in Middle Income Countries.

[6]   Weinstein, M.C., Siegel, J.E., Gold, M.R., Kamlet, M.S. and Russell, L.B. (1996) Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. Journal of American Medical Association, 276, 1253-1258.

[7]   Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L. and Torrance, G.W. (2015) Methods for the Economic Evaluation of Health Care Programmes. 4th Edition, Oxford University Press, Oxford.

[8]   Weinstein, M.C. and Stason, W. (1977) Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. New England Journal of Medicine, 296, 716-721.

[9]   Bonis, P.A.L. and Wong, J.B. (2017) A Short Primer on Cost-Effectiveness Analysis.

[10]   Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos and Departamento de Ciência e Tecnologia (2014) Diretrizes metodológicas: Estudos de avaliacao economica de tecnologias em saúde [Methodological Guideline: Economic Evaluaton of Health Technologies]. 2nd Edition, Ministério da Saúde, Brasília, 132 p.

[11]   Mogyorosy, Z. and Smith, P. (2005) The Main Methodological Issues in Costing. Health Care Services: A Literature Review. CHE Research Paper 7. Centre for Health Economics, Alcuin College, University of York, York.

[12]   Drummond, M., Barbieri, M., Cook, J., et al. (2009) Transferability of Economic Evaluations across Jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health, 12, 409-418.

[13]   World Bank (2016) PPP Conversion Factor, GDP (LCU per International $). International Comparison Program Database.

[14]   (2017) Historical Inflation Rates: 1914-2017. US Inflation Calculator.

[15]   The World Bank (2017) Inflation, Consumer Prices (Annual %).

[16]   The World Bank (2017) GDP (Current US$).

[17]   The World Bank. GDP per Capita (Current US$).

[18]   The World Bank. GDP per Capita, PPP (Current International $).

[19]   The World Bank. GNI per Capita, Atlas Method (Current US$).

[20]   Berraho, M., Najdi, A., Mathoulin-Pelissier, S., et al. (2012) Direct Costs of Cervical Cancer Management in Morocco. Asian Pacific Journal of Cancer Prevention: APJCP, 13, 3159-3163.

[21]   Cheikh, A., Majjaoui, S.E., Ismaili, N., et al. (2016) Evaluation of the Cost of Cervical Cancer at the National Institute of Oncology, Rabat. The Pan African Medical Journal, 23, 209.

[22]   Ricciardi, A., Largeron, N., Giorgi Rossi, P., et al. (2009) Incidence of Invasive Cervical Cancer and Direct Costs Associated with Its Management in Italy. Tumori, 95, 146-152.

[23]   Insinga, R.P., Ye, X., Singhal, P.K. and Carides, G.W. (2008) Healthcare Resource Use and Costs Associated with Cervical, Vaginal and Vulvar Cancers in a Large U.S. Health Plan. Gynecology Oncology, 111, 188-196.

[24]   Annemans, L., Rémy, V., Lamure, E., et al. (2008) Economic Burden Associated with the Management of Cervical Cancer, Cervical Dysplasia and Genital Warts in Belgium. Journal of Medical Economics, 11, 135-150.

[25]   Gobrane, H.B., Aounallah-Skhiri, H., Oueslati, F., Frikha, H., Achour, N. and Hsairi, M. (2009) Estimated Cost of Managing Invasive Cervical Cancer in Tunisia. Santé Publique, 21, 561-569.

[26]   Fonseca, A.J., Ferreira, L.P., Dalla-Benetta, A.C., Roldan, C.N. and Ferreira, M.L.S. (2010) Epidemiology and Economic Impact of Cervical Cancer in Roraima, a Northern State of Brazil: The Public Health System Perspective. Revista Brasileira de Ginecologia e Obstetricia, 32, 386-392.

[27]   Hayata, E., Seto, K., Haga, K., Kitazawa, T., Matsumoto, K. and Morita, M. (2015) Cost of Illness of the Cervical Cancer of the Uterus in Japan—A Time Trend and Future Projections. BMC Health Service Research, 15, 1-9.

[28]   Liu, N., Mittmann, N., Coyte, P.C., Hancock-Howard, R., Seung, S.J. and Earle, C.C. (2016) Phase-Specific Healthcare Costs of Cervical Cancer: Estimates from a Population-Based Study. American Journal of Obstetrics and Gynecology, 214, 615.e1-615.e11.

[29]   Novaes, H.M.D., Itria, A., Silva, G.A., et al. (2015) Annual National Direct and Indirect Cost Estimates of the Prevention and Treatment of Cervical Cancer in Brazil. Clinics, 70, 289-295.

[30]   Ostensson, E., Froberg, M., Leval, A., et al. (2015) Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination. PLoS ONE, 10, 1-15.

[31]   Holecki, T., Sobczyk, K., Nawrocki, S., Wozniak-Holecka, J., Skrzypek, M. and Bocionek, A. (2015) Costs of Malignant Cervical Cancer Curing in Poland in the Years 2011-2012 the Case of the Silesian Voivodeship. Polish Gynaecology, 86, 849-855.

[32]   Sánchez-Román, F.R., Carlos-Rivera, F.J., Guzmán-Caniupan, J.A., Escudero-De Los Ríos, P., Juárez-Pérez, C.A. and Aguilar-Madrid, G. (2012) Health Care Costs for Cervical Cancer. Revista Médica del Instituto Mexicano del Seguro Social, 50, 99-106.

[33]   Russell, L.B., Gold, M.R., Siegel, J.E., Daniels, N. and Weinstein, M.C. (1996) The Role of Cost-Effectiveness Analysis in Health and Medicine. Panel on Cost-Effectiveness in Health and Medicine. Journal of American Medical Association, 276, 1172-1177.

[34]   Negrini, D., Kettle, A., Sheppard, L., Mills, G.H. and Edbrooke, D.L. (2004) The Cost of a Hospital Ward in Europe: Is There a Methodology Available to Accurately Measure the Costs? Journal of Health Organization and Management, 18, 195-206.

[35]   Yabroff, K.R., Lund, J., Kepka, D. and Mariotto, A. (2011) Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. Cancer Epidemiology, Biomarkers & Prevention, 20, 2006-2014.